共 50 条
- [1] Real-world treatment patterns and total cost of care in Medicare patients with metastatic pancreatic ductal adenocarcinoma who received first-line FOLFIRINOXJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Hirsch, JaredCockrum, PaulTomicki, SamanthaDieguez, GabrielaBhatt, PrachiKim, George P.
- [2] Adverse events in real-world patients covered by Medicare with metastatic pancreatic ductal adenocarcinoma who received first-line FOLFIRINOXJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Dieguez, GabrielaTomicki, SamanthaCockrum, PaulHirsch, JaredBhatt, PrachiKim, George P.
- [3] Dosing patterns and treatment patterns in real-world patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first lineJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)MacEwan, Joanna P.Silver, MichelleCockrum, PaulSanders, ChadKim, George P.
- [4] First-line treatment patterns among patients with metastatic pancreatic ductal adenocarcinoma in the real-world settingJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Dennen, SyvartHarton, JoannaCockrum, PaulKim, George P.MacEwan, Joanna P.
- [5] Real-world overall survival and time to next treatment in patients with metastatic pancreatic ductal adenocarcinoma who received FOLFIRINOX and modified FOLFIRINOX in the first line.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 629 - 629Dennen, SyvartBoppudi Naga, Sai SritejaCockrum, PaulPaluri, Ravi Kumar
- [6] De-escalation and dose density in real-world patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first line.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 628 - 628Dennen, SyvartShao, AnranDennen, SyvartCockrum, PaulPaluri, Ravi Kumar
- [7] Adverse events in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first lineJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Kim, George P.Silver, MichelleSanders, ChadCockrum, PaulMacEwan, Joanna P.Duncan, Dan
- [8] Real-World Treatment Patterns, Healthcare Cost and Resource Utilization in First-Line Treatment of Metastatic NSCLC in the USJOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S400 - S401Chopra, D.Waterhouse, D. M.Sultan, I.Lonshteyn, A.Delea, T. E.Stollenwerk, B.
- [9] Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real WorldADVANCES IN THERAPY, 2022, 39 (12) : 5433 - 5452King, GentryIttershagen, StacieHe, LuyangShen, YingLi, FrankVillacorta, Reginald
- [10] Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real WorldAdvances in Therapy, 2022, 39 : 5433 - 5452Gentry KingStacie IttershagenLuyang HeYing ShenFrank LiReginald Villacorta